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Summary Take home message 254 characters (max 256) 
Time trends in worldwide asthma prevalence, measured in populations using 
standardised questionnaires and methods mainly increased from the mid-1990s to 
the mid-2000s. More recent data is needed and this will be provided by the Global 
Asthma Network Phase I, currently ongoing. 
 
Abstract 192 words (Max 250)  
This review of trends in worldwide asthma prevalence starts with defining asthma, 
how it is measured in populations and how it is analysed. Four population studies of 
asthma across at least two regions are described: European Community Respiratory 
Health Survey (ECRHS), The International Study of Wheezing in Infants (EISL), The 
International Study of Asthma and Allergies in Childhood (ISAAC) and World Health 
Survey (WHS). Two of these (ISAAC and WHS) covered all the regions of the world; 
each using its own standardised questionnaire-based methodology with cross-
sectional study design, suitable for large populations. EISL (2005 and-2012) and , 
ISAAC (1996-1997 and 2002-2003) have undertaken a second cross sectional 
population survey from which trends are available: EISL in three centres in two 
countries; ISAAC 106 centres in 56 countries (13-14 year olds) and 66 centres in 37 
countries (6-7 year olds). Key results from these studies are presented. 
Unfortunately there is no new worldwide new data outside of EISL since 2003. GBD 
estimates of asthma prevalence have varied greatly. Recent reliable worldwide data 
on asthma prevalence is needed and this will be provided by the Global Asthma 






What is asthma prevalence and how is it measured? 
The definition and classification of asthma has been the subject of many approaches 
and opinions for several decades (1), with variable airways obstruction being its key 
feature.  The essential features of asthma are captured by the Global Initiative for 
Asthma (GINA) describing it as “a heterogeneous disease, usually characterised by 
chronic airway inflammation. Asthma is defined by the history of respiratory 
symptoms such as wheeze, shortness of breath, chest tightness and cough that vary 
over time and in intensity, together with variable expiratory airflow limitation”(2).  
Asthma symptoms most commonly first develop in early childhood. Children of pre-
school age often wheeze with viral infection, but only about half of them go on to 
have characteristic asthma at school age. Children who have frequent or persistent 
wheeze are more likely to have evidence of airway inflammation and remodelling, 
impaired lung function, and persistently troublesome symptoms into adulthood (1, 3). 
The underlying mechanisms of asthma are still not well understood. About one-half 
of people with asthma have underlying allergic (4) and the other half non-allergic 
mechanisms (5) and this latter type is more common in low- and middle income 
countries (LMICs). It is unclear whether asthma is a single disease, or if it is in fact a 
grouping of different conditions which all result in the same clinical effect (5, 6). 
Despite this, most people with asthma symptoms improve with asthma medicines, 
and the use of the term asthma as a clinical diagnosis is still useful in most patients 
because it opens the door to appropriate management to reduce disease burden (7). 
Asthma prevalence is simply the proportion of the population, or a subgroup of the 
population (e.g. 13-14 year olds) who have the condition at a particular time. This 
usually requires assessment of symptoms over a set period (e.g. the past year) as 
many asthmatics have intermittent symptoms and may not have them on the day of 
study.  
The diagnosis of asthma involves an overall assessment of the patient's medical 
history, physical examination, and usually a measure of lung function and often a 
test of response to inhaled bronchodilator. More recently biomarkers such as 
exhaled nitric oxide have been added in some settings. There are no universally 




diagnosis of asthma varies between doctors, between locations, between countries, 
and over time, and there are pitfalls(8). There are reports of underdiagnosis (9) and 
overdiagnosis (10) of asthma in children and in adults (11). In young children who 
commonly wheeze, only about half will go on to have asthma at school age, so there 
is caution about using the term asthma in that age group. Nevertheless the term 
preschool asthma is recommended for those who respond to essential asthma 
medicines (12, 13), and this term can be reviewed regularly. 
Therefore for population-based studies of asthma, these are usually done outside of 
the preschool age group. Where doctor diagnosis is not practicable, questionnaires 
are the tool of choice. Questions about more recent symptoms (in the past 12 
months) are more reliable than questions about symptoms in the past, because they 
reduce errors of recall (14, 15). 
Written questionnaires have therefore been the principal instrument for measuring 
asthma symptom prevalence in community surveys which must be standardised to 
enable valid comparisons – that is conform to a set of questions in a questionnaire 
format, and delivered according to a specified protocol including details about 
sampling frame, age and size of sample. This is especially important in examining 
trends over time, as changes in methodology could be the explanation for variation 
over time rather than it being a true change. In homogeneous populations 
questionnaires have been standardised, validated, and shown to be reproducible 
(16). A number of symptoms including wheezing, chest tightness, breathlessness, 
and coughing with or without sputum are recognised by physicians as indicative of 
asthma. Of these the most important symptom for the identification of asthma in 
epidemiological studies is wheezing. A large number of such questions have been 
used in epidemiological surveys.  
A critical appraisal of repeated cross-sectional surveys of asthma in children and 
young adults 1983-1996 found 16 studies of interest. Only studies in United 
Kingdom, Australia and New Zealand reported trends in current wheeze, the 
remainder were dependent upon asthma diagnosis which has wide influences (8, 
17). The urgent need for standardised methodologies to estimate asthma prevalence 
from symptoms in a wide range of settings in the world led to the development of the 





Standardised methodology for asthma prevalence 
European Community Respiratory Health Survey (ECRHS)  
In adults the European Community Respiratory Health Survey (ECRHS) (18) built on 
the questions developed for the International Union against Tuberculosis and Lung 
Diseases (IUATLD) (19). ECRHS planned to answer specific questions about the 
distribution of asthma and health care for adults with asthma in the European 
Community. In ECRHS I (1991-3) participating centres selected an area defined by 
pre-existing administrative boundaries with a population of at least 150,000. When 
possible, an up-to-date sampling frame was used to randomly select at least 1,500 
males and 1,500 females, aged 20–44 yrs (20). The Screening Questionnaire was 
generally sent by post and self-administered. A smaller random sample of those 
subjects were invited to attend for a more detailed interviewer-administered 
questionnaire and several tests. Engagement in ECRHS extended beyond Europe; 
participating locations were 48 centres in 22 countries of which 17 were Europe and 
five elsewhere: Algeria, Australia, India, New Zealand, USA, a total of 137,619 
participants (20). The standardised methodology enabled ECRHS to repeat the 
survey after 10 years (ECRHS II) (21)and again after 20 years (ECRHS III) (22); 
each of these surveys were done in the same individuals over time, thus making it a 
longitudinal study. While the three phases of ECRHS are valuable in their own right, 
they are unsuitable for examining time trends in population asthma prevalence, 
where repeated cross-sectional studies are needed. 
World Health Survey (WHS) 
The largest and widest source of information on asthma in adults in low-income 
countries comes from the World Health Survey (WHS) implemented by the World 
Health Organization in 2002-2003 (23). The WHS investigated many diseases as 
well as asthma. Instruments were developed and household face-to-face surveys 
were done in most countries, randomly selected households were contacted and a 
single person from each household was interviewed (24). There was a total of 
178,215 adults aged 18 to 45 years from 70 countries who responded to questions 
about asthma and related symptoms. (25). The prevalence of asthma was based on 




clinical/treated asthma, and wheezing in the past 12 months. This study showed that 
there are very wide variations in the prevalence of wheeze and asthma regardless of 
overall national income. Overall, the prevalence of symptoms and diagnosis showed 
a U-shaped pattern with the largest prevalence reported in low- and high-income 
countries. The global prevalence rates were 4.3% doctor diagnosed asthma, 4.5% 
clinical/treated asthma and 8.6% wheezing in adults, and varied by as much as 21-
fold amongst the 70 countries. The authors concluded that these findings support the 
need for continued global respiratory illness surveillance for disease prevention, 
health policy and management. However there has been no repetition of the WHS 
despite its valuable results, standardised methodology suitable for further cross-
sectional surveys, and therefore there is no time trend data. 
The International Study of Asthma and Allergies in Childhood (ISAAC) 
ISAAC was founded to maximize the value of epidemiological research into asthma 
and allergic disease, by establishing a standardized methodology and facilitating 
international collaboration (26). It built on previous work and established its own 
standardised core asthma questionnaire, along with questionnaires on rhinitis and 
eczema (26). From the outset one of its goals was measuring time trends, so the 
methodology had to be sufficiently robust to achieve this. Its specific aims were to 
describe the prevalence and severity of asthma, rhinitis and eczema in children living 
in different centres, and to make comparisons within and between countries; to 
obtain baseline measures for assessment of future trends in the prevalence and 
severity of these diseases; and to provide a framework for aetiological research into 
genetic, lifestyle, environmental, and medical care factors affecting these diseases. 
The ISAAC design comprised three phases. Phase One (1994-95) assessed the 
prevalence and severity of asthma and allergic disease. Phase Two investigated 
possible aetiological factors, particularly those suggested by the findings of Phase 
One. Phase Three (2001-2003) was a repetition of Phase One to assess trends in 
prevalence. 
Two age groups of school children participated: The compulsory age group was 13-
14 year olds (adolescents), who self-completed questionnaires at school and 
optional 6-7 year olds (children), who took questionnaires home to be completed by 
their parents, and. In Phase One an international clinical asthma video questionnaire 




with the written questionnaires, as it obviated the need to describe symptoms 
verbally and. was also used in Phase Three. The written and video questions have 
been compared for their prediction of bronchial hyper-responsiveness in different 
ethnic groups (27-31).  
ISAAC Phase One involved over 700 000 adolescents and children, from 156 
centres in 56 countries. Schools were the sampling units with a minimum of 10 
schools randomly selected per centre (or all schools used). Students were selected 
either by grade/level/year, where classes with most children of the age group were 
selected, or by age group alone. A high response rate was required  for valid 
estimates of population prevalence and in adolescents the use of passive consent 
achieved higher response rates than active consent (32) 
The core ISAAC asthma questions were: “Have you (has your child) ever had 
wheezing or whistling in the chest at any time in the past?”; “Have you (has your 
child) had wheezing or whistling in the chest in the past 12 months?; and “Have you 
(has your child) ever had asthma?”. Those self diagnostic questions are qualified by  
severity and frequency questions such as: “How many attacks of wheezing have you 
(your child) had in the past 12 months?”; “How often, on average, has your (your 
child’s) sleep been disturbed due to wheezing?”; “In the past 12 months, has 
wheezing ever been severe enough to limit your (your child’s) speech to only one or 
two words at a time between breaths?” (33).  
The simplicity of the ISAAC methodology, and its relatively low cost enabled it to be 
undertaken in most settings around the world, more than in any other 
epidemiological study of asthma. It was hailed as “a tremendous development in 
encouraging participation in research across the world…The concept of ISAAC was 
very simple at the outset—to develop a simple frame to undertake standard 
measurements and to make comparisons from one location to another, across 
geographic, cultural and linguistic boundaries. It operated with a decentralised 
structure, with partners in the venture encouraging groups in each geographic area. 
The base of the frame was very ‘light’, encompassing straightforward techniques that 
could be undertaken at any location and with few financial resources, enabling truly 




The key asthma questions (wheezing in the chest ever and in the past 12 months) 
have been validated against the clinical diagnosis of asthma and compared to the 
bronchial hyper-responsiveness (BHR) test. The Youden index (Y-index), the best 
statistical for these comparisons (35), was 66% (sensitivity 85%, specificity 81%) 
(36), which was higher than the one achieved for the IUATLD questionnaire (53%) 
(19) and one of the highest in validation studies from 1971 to 2014 (37). The Y-index 
for the validation of the questions in Spanish (the second most commonly used 
language in ISAAC) was 57% (38). Compared to the BHR test (hypertonic saline) the 
ISAAC questionnaire showed greater sensitivity (85% vs. 54%), slightly lower 
specificity (81% vs. 89%) and a substantially higher Y-index (66% vs. 43%), with the 
gold standard being physician-diagnosed asthma (36). 
ISAAC had a very strict protocol for the translation of questions, and back translation 
to English, and these were compared.. The results of a study of ISAAC translations 
(39) showed that important deviations from the exact meaning of the core questions 
were very low, although  minor deviations from literal translations of English 
(particularly “wheezing”) were permitted in order to maintain the original meaning,. 
The methodology, including power and sample size together with organisation of 
centres and their interaction with the data centres was carefully documented (33)  
A comparison of prevalence between 17 countries that participated in both ISAAC 
and ECRHS  showed that although there were differences in the absolute levels of 
prevalence observed, there was good general agreement on the patterns of asthma 
prevalence internationally (40). These findings support the validity of the two studies. 
International Study of Wheezing in Infants (EISL) 
Wheezing in young children is very common, sometimes causing considerable 
morbidity, and sometimes leading on to asthma. The International Study of 
Wheezing in Infants (Estudio Internacional de Sibilancias en Lactantes, EISL) is the 
largest multi-centre study of wheezing in the first year of life (12). It was based on the 
tools developed by ISAAC, and validated for this age group (41). The questionnaire 
was administered to parents in primary health centres when children attended to 
receive the MMR vaccination at ages 12 to 15 months (depending on countries), 




about the prevalence of wheezing and treatment approaches of recurrent wheezing. 
Data from this cross-sectional study in 2005 included 30,093 children in 17 centres: 
25,030 in 12 centres in Latin America and 5,063 from 5 centres in Europe and 
published in 2010 (among many International prevalence of recurrent wheezing 
during the first year of life: variability, treatment patterns and use of health resources 
(42, 43).  
A modified, shortened Portuguese version of the EISL-WQ in children up to 36 
months of age in São Paulo, Brazil, was validated and its usefulness in diagnosing 
probable asthma in these children was established (44). The standardised methods 
have enabled, in children under three, time trends in wheezing and probable asthma 
to be determined. Unfortunately only three of the centres participating in EISL phase 
I were able to provide data on time trends seven years later in 2012 (45). In all three 
centres: Sao Paulo (Brazil), Curitiba (Brazil) and Santiago (Chile) the prevalence of 
any wheezing, recurrent wheeze and wheezing during the first 3 months of life 
decreased from 2005 to 2012 (45). 
 
Analysis of time trends in asthma prevalence 
To analyse time trends in asthma prevalence it is essential that the same methodology 
is used to compare the two or more time points and to compare the trends in the 
various centres or regions under study. Here we briefly describe the methodology used 
to analyse time trends data in ISAAC: two cross-sectional studies 5-10 years apart 
using the same sampling frame and methodology (46), before proceeding to 
summarize the findings of these analyses. 
In ISAAC, centres who conducted both ISAAC Phases Three and  One conducted the  
both phases following the same protocol. For  time trend analyses, the data for 
adolecents and children were analysed separately. In each centre symptom 
prevalences  were calculated by dividing the number of positive responses to each 
question by the number of completed questionnaires. The annual change in symptom 
prevalence was calculated by taking the difference between the Phase One andThree 
prevalences and dividing by the number of years between the two surveys. For  




of the variance of the change. The key findings were also presented as “ranking plots” 
showing the change in symptom prevalence  (e.g. current wheeze) for each centre by 
country, with countries ordered by their average prevalence (for all centres combined) 
across Phases One and Three. The average prevalence  was used to order countries 
since this is statistically independent from the change in prevalence (between Phases 
One and  Three) whereas the Phase One prevalence was not (46).  
ISAAC time trends in asthma prevalence 
ISAAC Phases One and Three time trends in prevalence were estimated for 3 
related conditions: asthma, rhinitis and eczema in 304 679 13-14 year old 
adolescents from 106 centres in 56 countries and 193 404 6-7 year old children from 
66 centres in 37 countries (47). Replication of standardised methodology is very 
important; comparisons between ISAAC Phase Three and Phase One were found to 
be good (48). 
Figure 1 shows a world map of changes for asthma symptoms. Most centres showed 
a change in prevalence of 1 or more SE for at least one condition, with increases 
being twice as common as decreases, and children than in the adolescents, and at 
most levels of mean prevalence. An exception was asthma symptoms in the 
adolescents, in which decreases were more common at high prevalence. For both 
age-groups, more centres showed increases in all three conditions more often than 
showing decreases, but most centres had mixed changes. Despite some increase in 
the proportion of children and adolescents with symptoms of asthma, 
rhinoconjunctivitis and eczema, the pattern between the three diseases has not 
changed much, suggesting that similar factors may be affecting them at a global 
level (49). 
For asthma (46) the mean worldwide symptom prevalence of current wheeze in the 
last 12 months changed slightly from 13.2% to 13.7% in adolescents  (mean 
increase of 0.06% per year) Figure 2a and from 11.1% to 11.6% in children  (mean 
increase of 0.13% per year). There was also little change in the mean symptom 
prevalence of severe asthma Figure 2b or the symptom prevalence measured with 
the asthma video questionnaire Figure 3b. But asthma ever increased Figure 3a. 




patterns. In Western Europe, current wheeze decreased by 0.07% per year in 
adolescents but increased by 0.20% per year in children.. The corresponding 
findings per year for the other regions in  adolescents and children, respectively, 
were: Oceania (20.39% and 20.21%); Latin America (+0.32% and +0.07%); Northern 
and Eastern Europe (+0.26% and +0.05%); Africa (+0.16% and +0.10%); North 
America (+0.12% and +0.32%); Eastern Mediterranean (20.10% and +0.79%); Asia-
Pacific (+0.07% and 20.06%); and the Indian subcontinent (+0.02% and +0.06%). 
There was a particularly marked reduction in current asthma symptom prevalence in 
English language countries (20.5% and 20.1%). Similar patterns were observed for 
symptoms of severe asthma. However, the percentage of children reported to have 
had asthma at some time in their lives increased by 0.28% per year in adolescents 
and by 0.18% per year in children. 
These findings indicate that international differences in asthma symptom prevalence 
reduced, particularly adolescents, with decreases in prevalence in English speaking 
countries and Western Europe and increases in prevalence in regions where 
prevalence was previously low. Although there was little change in the overall global 
prevalence of current wheeze, the percentage of children and adolescents reported 
to have had asthma increased significantly, possibly reflecting greater awareness of 
this condition and/or changes in diagnostic practice. The increases in asthma 
symptom prevalence in Africa, Latin America and parts of Asia indicate that the 
global burden of asthma is continuing to rise, but the global prevalence differences 
are lessening.  
Two subsequent studies using ISAAC methodology have done a third survey: In 
Brazil adolescents in Curitiba, Recife and São Paulo were studied in ISAAC Phases 
One (1994) and Three (2003) and again in 2012 (46). Over the 18 year period the 
prevalence of current asthma symptoms reached a peak and then levelled off, 
however the prevalence of more severe and atypical forms of asthma increased. In 
South-Santiago, Chile, ISAAC Phases One and Three were completed, and a further 
survey of asthma in adolescents using ISAAC methodology in 2015 (50). The 
prevalence of current asthma in adolescents from the studied area continues to 
increase whereas severe asthma and asthma with exercise decreased. 




The Global Asthma Network (GAN) was established in 2012. Its’ core activities are 
global surveillance of asthma prevalence, severity, management and risk factors; 
promotion of standard case management of asthma; operational research; capacity 
building; engagement with policy makers; and access to affordable quality-assured 
essential medicines. The four main hypotheses of GAN Phase I are: 1) globally, the 
burden of asthma is changing in adults and children; 2) there is large variation in the 
diagnosis of asthma; 3) in many locations, asthma is under-diagnosed and its 
management is suboptimal; and 4) there are potentially remedial risk factors of 
asthma. 
GAN Phase I, started in 2017, intentionally builds on the ISAAC findings by using the 
same cross-sectional methods: information on asthma, rhinitis and eczema 
prevalence and severity, with additional questions on diagnoses, asthma emergency 
room visits, hospital admissions, management and use of asthma essential 
medicines. The same age groups (adolescents and children) as ISAAC are used, 
and their parents. This is the first global monitoring of asthma in children and adults 
since 2003, built on the ISAAC and ECRHS questionnaires for children and adults 
(51), with the same core questions for asthma. The questionnaire is self-completed 
by adolescents  and parents of children and their parents. 
GAN  has completed data collection for Phase I in many centres and countries,  and 
some also participated in ISAAC. The worldwide analyses have not yet been 
completed or published, but anticipated in 2021. There have been three GAN Phase 
I studies with previous ISAAC data published: In Bangkok, Thailand, there was little 
change between ISAAC Phase Three and GAN Phase I study (52). In a north part of 
Mexico City (Mexico) with high asthma prevalence GAN Phase I was undertaken 10 
years after ISAAC Phase Three (53). There was a 7.9% increase in the prevalence 
of asthma symptom, and almost half of the adolescents and children presenting with 
symptoms had experienced more than four episodes per year, but less than 50% of 
adolescents and children with asthma symptoms had been diagnosed with this 
disorder, suggesting under-diagnosis. In a further study of four Mexican centres the 
prevalence of asthma and its symptoms increased from ISAAC Phase Three to GAN 





Global Burden of Disease Study (GBD) 
The GBD has reported estimates of the global asthma prevalence, deaths and 
disability adjusted life years (DALYs) between 1990 and 2017. In the GBD 2015 
systematic analysis data were available for 121 countries (55), but, apart from 
ISAAC, references for these studies are not given; it is unclear how many of these 
other studies had undertaken time trend surveys with standardised methodology. 
The GBD case definition for asthma was a reported diagnosis by a physician, with 
wheezing in the past 12 months. 
GBD asthma prevalence trends. 
The GBD estimates of the global prevalence of asthma have varied considerably 
between the sequential reports: 2000 220.4 million (56), 2005 327.1 million (57), 
2010 334.2 million (58), 2013 241.7 million (59), 2015 358.2 million (55), 2016 339.4 
million (57) and 2017 272.7 million (60).  Such large variations between 2010 and 
2017, of up to 109 million, are unexplained, but are likely to be due to changes in 
analytical methods, as there have been no new large scale standardised data on 
asthma prevalence during this period. Moreover it is inconceivable that the global 
prevalence could have swung down up and down by such large amounts. The GBD 
2017 modelling (60) shows relatively smaller variations in estimated prevalence 
2000-2017 than the variations in the GBD counts in separate analyses during the 
same time period. For an earlier period, mid-1990s to early 2000s, GBD 2017 back-
extrapolates a decline in global prevalence (all ages) from ~3.5% to ~3.3% for males 
and from ~4.0% to ~3.6% for females. At that time there was some standardised 
worldwide prevalence time-trend data from adolescents and children in ISAAC 
Phases One to Three (46), suggesting a rise in prevalence of asthma symptoms in 
most centres – see discussion earlier in this article. During a similar time period there 
was little increase in asthma symptoms in adults (21). The swinging GBD estimates 
illustrate how vital it is to have new and ongoing standardised measurements of 
asthma prevalence in populations in representative countries around the world.  
GBD asthma mortality trends 
The GBD estimates of the global asthma deaths have degrees of variation which 




their accuracy: 1990 380,200 (61) and 504,300 (62), 2000 218,000 (56), 2005 
449,900 (63), 2010 345,700 (61), 2013 489,000 (62), 2015 397,100 (55, 63), 2016 
420,000 (64), 2017 495,000 (65).  
GBD asthma DALYs trends 
DALYs are the sum of years of life lost (the years of healthy life lost due to asthma 
death) and years lived with disability (the prevalence multiplied by the disability 
weight for asthma). To calculate the disability weight for asthma, the proportions of 
mild, moderate and severe asthma disease need to be known as they have different 
disability weights. In GBD the source data for this is unclear. From 2005 to 2017 the 
DALYs from asthma have been relatively stable while earlier estimates fluctuated: 
1990 21.469 million (66), 13.858 million (56), 2005 22.2404 million (67) and 26.8597 
million (68), 2010 22.459 million (66), 2013 22.1827 million (67), 2015 26.1688 
million (55, 68), 2016 23.8409 Hay (69), 2017 22.8 million (70).  
 
Relationship of time trends in hospital admissions and mortality to time trends 
in asthma prevalence  
National hospital admission statistics are lacking for most LMICs. Historically, the 
relationship between asthma prevalence, severity and admission rates in higher-
income countries has been complex, but changes in the admission rate over time 
correlate (albeit imperfectly) with changes in the prevalence and severity of 
childhood asthma.  
For countries with ISAAC study centres participating in both Phase One and Three, 
Figure 4 plots the annual change in childhood hospital admission rates against the 
change in the prevalence of wheeze causing adolescents to wake at night at least 
once a week. Over this period (approximately 1995-2002), admission rates declined 
in all these countries except Hong Kong and Poland. There was a significant positive 
correlation between the decline in prevalence of severe asthma symptoms between 
Phases One and Three and the decline in the corresponding national admission 




In most, but not all, European countries, age-standardised asthma admission rates 
declined from 2001-2005 to 2011-2015, some countries showing more than a twofold 
reduction (71). The relative decline was of similar magnitude among under-20s and 
adults (aged 20+). The continuing decline in asthma admission rates among children 
and adolescents is part of a longer-term rise and fall, peaking in the early 1990s 
which bears no temporal relationship to two epidemics of asthma mortality (in the 
1960s and the 1980s) nor to time trends for self-reported asthma prevalence (72). 
However, data from the United Kingdom showed a peak of primary care contacts for 
acute asthma, particularly among children, in the early 1990s, similar to that of 
asthma hospital admissions (73). This is consistent with a rise and fall in the 
incidence of asthma attacks in the community, rather than simply a change in 
patterns of referral to secondary care, or a reduction in the severity threshold for 
admission to the hospital ward. 
Comparison of within-country changes in asthma mortality and admission rates for 
24 European countries over the decade 2001-2005 through 2011-2015 shows no 
correlation between time trends in these two indicators of more severe asthma (74). 
Over this period, national age-standardised death rates for asthma reduced to a 
greater extent (in relative terms) than did age-standardised asthma admission rates, 
reflecting a global pattern in which asthma mortality rates approximately halved in 
most countries from 2001-2005 to 2011-2015. A similar relative decline was seen in 
the age group 5-34 years (74, 75), upon which attention often focuses because 
diagnostic confusion between asthma and other fatal respiratory diseases is least 
likely in this age group. 
When national asthma mortality rates for children were compared with the asthma 
symptoms prevalence and severity data for ISAAC Phase One centres in the same 
countries, a significantly positive correlation was found between childhood asthma 
mortality and the prevalence of more severe asthma symptoms in both 6-7-year-olds 
(29 countries) and 13-14-year-olds (38 countries) (76). Such comparisons need to be 
interpreted with caution, because ISAAC centres are not necessarily representative 






To address the global burden of asthma, sequential standardised studies are vital, 
and this data needs to be obtainable in all settings around the world. Four studies 
have achieved this prospectively, within and between population, collecting data to 
make estimates of asthma prevalence: EISL, ECRHS, ISAAC and WHS. Only 
ECRHS and ISAAC have been able to repeat these standardised surveys in large 
numbers of countries, with only ISAAC having a truly global reach to estimate 
worldwide trends. However there have been no further global field studies since 
2002-3 until GAN Phase I which follows ISAAC methodology and is well underway. 
This is expected to contribute to our understanding of asthma. 
 
Acknowledgements 
We are grateful to the children, parents, adults who willingly participated with the 
help of schools and field workers in ECRHS, EISL, ISAAC and WHS, to enable 



























Figure 4  
Annual change in hospital admission rates for childhood asthma (ages 5-14) by 
change in prevalence of nocturnal wheezing among 13-14 year olds in countries with 
one or more ISAAC centres providing prevalence data for both ISAAC Phase One 
(around 1995) and ISAAC Phase Three (around 2002). 
Sources: National admissions data from Anderson HR et al. IJE 2008; (updated by 
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